Stocks to sell

If I had a pet, I could love Zomedica (NYSEAMERICAN:ZOM) and its services — but its stock is another story. In March, I pointed out that ZOM stock is “overvalued and a risky bet” because of the low acceptance rate of its Truforma platform. So far, my opinion hasn’t changed. Source: didesign021 / Shutterstock.com In

When Skillz (NYSE:SKLZ) stock traded at a 52-week low last week, it validated the bears. Source: Rawpixel.com/Shutterstock.com The stock has a short float of more than one-fifth. How did the skeptics know that this electronic gaming and multimedia firm would fall by so much? Momentum investors tried to lift SKLZ stock a few times in

While virtually every business sector suffered devastating losses during the initial onslaught of the novel coronavirus pandemic, among the worst-hit industries was food services. Suddenly, once-popular eating establishments found themselves staring at zero traffic, sending restaurant stocks cratering. Fortunately, gradual acclimatization and the vaccine rollout helped bring the sector back from the brink. However, economic

Detroit’s Rocket Companies Inc (NYSE:RKT) has made a splash in 2021 as one of the year’s classic “meme” stocks. The highlight of this action was a single-day surge of 71% at the start of March. Serious investors will point to the fact that RKT stock is much more than a Reddit-fueled story. After all, the

Fuel cell specialist Plug Power (NASDAQ:PLUG) has enjoyed a healthy run-up in its value recently. PLUG stock has grown over 24% in value in the past one month, spurred by management’s lofty claims at the recent Plug Symposium. However, though some seem to be buying into the company’s narrative, to me things just don’t add

Cannabis company Tilray (NASDAQ:TLRY) is undeniably a disappointment. Meme traders sent TLRY stock to an unsustainable high of $67 in February. Since then, the stock has fallen steadily. Source: Jarretera / Shutterstock.com As this Canadian cannabis firm aims to expand to the U.S., should the owners of its stock hold onto their shares? The Bearish

MicroVision (NASDAQ:MVIS) is a company seeking to commercialize light detection and ranging (lidar) technology. The company has been in business since the 1990s and has little to show for it. MVIS stock peaked around $500/share during the 2000 dot-com bubble, and trades at a tiny fraction of that today. Source: temp-64GTX/Shutterstock.com That said, MicroVision has

As was the case last month, GameStop (NYSE:GME) stock has managed to perform relatively well. That is, considering how the conditions that enabled the “to the moon” rally earlier this year are no longer in play. Source: TY Lim / Shutterstock.com Yes, shares in this video game retailer remain one of the most talked about

Cloudflare (NYSE:NET) stock keeps pushing higher, even though its valuation is in nosebleed territory. I want to recommend investors buy NET stock, but I can’t do that in good conscience. In fact, at this point, the only thing I can do is point out how incredibly overvalued it seems to be, even as it continues

Lemonade (NASDAQ:LMND) stock has caught investors’ attention, and for pretty good reason. Source: Stephanie L Sanchez / Shutterstock.com If Amazon’s (NASDAQ:AMZN) taught us anything over the past few decades, it’s the power of disruption, and the value of recognising it early. That’s part of the reason that insurance disruptor Lemonade is so attractive. LMND stock

Cloudflare (NYSE:NET) stock has performed extremely well in 2021. As of Oct. 20, it’s up 130%, opening at $175.80. With this in mind, many investors think that there are only two scenarios for NET stock. Either this momentum will continue, sending prices higher, or more prudent, conservative investors and traders will wait for a dip

It is no secret that Hyliion Holdings (NYSE:HYLN) stock has become a massive disappointment. Source: Hyliion media It fell dramatically leading up to its special purpose acquisition company (SPAC) merger back in late 2020, after rising in equally dramatic fashion after the initial announcement.  Prices rocketed from under $10 per share to a high nearing

UiPath (NYSE:PATH) is a $25.79 billion technology stock that is draining out cash and seems to be having trouble with top-line growth. This means that the company may have trouble maintaining this high valuation. As a result, PATH stock is likely to keep falling. Source: dennizn / Shutterstock.com In fact, from its peak of $85.00

After months of sideways price action, Covid-19 vaccine play Ocugen (NASDAQ:OCGN) stock is zooming higher once. Source: shutterstock.com/PhotobyTawat The big development is a likely Emergency Use Listing (EUL) from the World Health Organization (WHO) for Covaxin. Developed in India by Bharat Biotech, Ocugen holds the U.S. and Canadian rights to market this vaccine. An EUL certainly

Just over a year ago, Hyliion (NYSE:HYLN) was one of the hottest electric vehicle special-purpose acquisition company (SPAC) plays out there. Just before its “de-SPACing,” excitement over this maker of electric trucks and powertrains briefly sent HYLN stock to prices over $50 per share. Source: Shutterstock Flash forward back to now, and where are shares changing

Wish.com parent company ContextLogic (NASDAQ:WISH) stock has been a disaster since its initial public offering. Source: sdx15 / Shutterstock.com Wish went public at an IPO price of $24 in December 2020. The stock rallied as high as $32.85 in February during the Reddit WallStreetBets trading fury. Since then, the stock has dropped like a rock.

With shares moving up following the acquisition of Nanotech, is it time to buy Meta Materials (NASDAQ:MMAT) stock, ahead of its revenues taking off? Not so fast. It’s still down big from the high prices it hit when it first appeared on the radar of meme stock investors. But at $5.31 per share, this smart

OpenDoor (NASDAQ:OPEN) stock is the kind of name I’ve learned to avoid. Source: PREMIO STOCK/Shutterstock.com Over my years of investing, I’ve learned–in some cases, the hard way — that buying stocks on weakness is really the best and easiest way to make money in the market. Conversely, buying risky names that are riding positive momentum

A few months ago, the Federal Reserve was talking about “transitory” inflation. The governors at the Fed meant that while inflation was rising swiftly, it wasn’t going to last. But inflation kept rising at a brisk clip and the Fed started to be less sanguine about the transitory nature of inflation. It hedged by telling

Ocugen (NASDAQ:OCGN) is a small biotech firm. For years, it tried unsuccessfully to commercialize therapies for eye diseases. However, in 2020, it ended a Phase 3 trial on that front and pivoted to Covid-19. Its first effort in that regard, Covid-19 testing, totally failed to take off. The company is nothing if not persistent, however,